Prevalence and Incidence of Dementia in Patients With Non-Overtly Functional Adrenal Tumours.

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2024-12-25 DOI:10.1111/cen.15186

Hadis Mirzaei, Jekaterina Patrova, Buster Mannheimer, Jonatan D Lindh, Henrik Falhammar

{"title":"Prevalence and Incidence of Dementia in Patients With Non-Overtly Functional Adrenal Tumours.","authors":"Hadis Mirzaei, Jekaterina Patrova, Buster Mannheimer, Jonatan D Lindh, Henrik Falhammar","doi":"10.1111/cen.15186","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the prevalence and incidence of dementia in patients with non-overtly functional adrenal tumours (NOFATs).Design: A national retrospective register-based study was conducted on patients diagnosed with NOFAT and controls diagnosed between 2005 and 2019, in Sweden. Individuals diagnosed with overt adrenal hormone excess or previous malignancies were excluded. Sensitivity analyses were performed in subgroups with a combination of gallbladder/biliary tract/pancreatic disease. and acute appendicitis, as well as 3- and 12-months of malignancy-free survival.Measurements: Prevalence and incidence of dementia. The secondary outcomes were Alzheimer's disease and vascular dementia.Results: Among 20,390 cases, 12,120 (59.4%) were women, and the median (IQR) age was 66 (57-73) years. Among the 125,392 controls, 69,994 (55.8%) were women and the median (IQR) age was 66 (57-73) years. Patients with NOFATs had a lower prevalence of dementia compared to controls (odds ratio [OR] 0.58, 95% CI 0.50-0.68, adjusted OR [aOR] 0.47, 95% CI 0.40-0.56). During the follow-up period (median 4.9 years, IQR 2.2-8.2), incidence of dementia was similar in NOFATs and controls (hazard ratio [HR] 1.05, 95% CI 0.97-1.15, adjusted HR [aHR] 1.06, 95% CI 0.97-1.15). Similar results obtained for Alzheimer's dementia (aOR 0.44, 95% CI 0.34-0.57; aHR 0.94, 95% CI 0.80-1.10) and vascular dementia (OR 0.71, 95% CI 0.52-0.94, aOR 0.48, 95% CI 0.35-0.64; HR 1.29, 95% CI 1.08-1.53, aHR 1.13, 95% CI 0.95-1.35) as well as in the sensitivity analyses. Adrenalectomy did not change the results.Conclusion: NOFAT was not associated with an increased risk of dementia.","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cen.15186","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the prevalence and incidence of dementia in patients with non-overtly functional adrenal tumours (NOFATs).

Design: A national retrospective register-based study was conducted on patients diagnosed with NOFAT and controls diagnosed between 2005 and 2019, in Sweden. Individuals diagnosed with overt adrenal hormone excess or previous malignancies were excluded. Sensitivity analyses were performed in subgroups with a combination of gallbladder/biliary tract/pancreatic disease. and acute appendicitis, as well as 3- and 12-months of malignancy-free survival.

Measurements: Prevalence and incidence of dementia. The secondary outcomes were Alzheimer's disease and vascular dementia.

Results: Among 20,390 cases, 12,120 (59.4%) were women, and the median (IQR) age was 66 (57-73) years. Among the 125,392 controls, 69,994 (55.8%) were women and the median (IQR) age was 66 (57-73) years. Patients with NOFATs had a lower prevalence of dementia compared to controls (odds ratio [OR] 0.58, 95% CI 0.50-0.68, adjusted OR [aOR] 0.47, 95% CI 0.40-0.56). During the follow-up period (median 4.9 years, IQR 2.2-8.2), incidence of dementia was similar in NOFATs and controls (hazard ratio [HR] 1.05, 95% CI 0.97-1.15, adjusted HR [aHR] 1.06, 95% CI 0.97-1.15). Similar results obtained for Alzheimer's dementia (aOR 0.44, 95% CI 0.34-0.57; aHR 0.94, 95% CI 0.80-1.10) and vascular dementia (OR 0.71, 95% CI 0.52-0.94, aOR 0.48, 95% CI 0.35-0.64; HR 1.29, 95% CI 1.08-1.53, aHR 1.13, 95% CI 0.95-1.35) as well as in the sensitivity analyses. Adrenalectomy did not change the results.

Conclusion: NOFAT was not associated with an increased risk of dementia.

查看原文本刊更多论文

非显性功能肾上腺肿瘤患者痴呆的患病率和发病率。

目的：探讨非显性功能肾上腺肿瘤（nofat）患者痴呆的患病率和发病率。设计：在瑞典，对2005年至2019年诊断为NOFAT的患者和对照组进行了一项基于全国回顾性登记的研究。诊断为明显肾上腺激素过量或既往恶性肿瘤的个体被排除在外。对合并胆囊/胆道/胰腺疾病的亚组进行敏感性分析。和急性阑尾炎，以及3个月和12个月的无恶性肿瘤生存。测量：痴呆的患病率和发病率。次要结局是阿尔茨海默病和血管性痴呆。结果：20390例患者中，女性12120例（59.4%），中位（IQR）年龄为66（57 ~ 73）岁。在125,392例对照中，69,994例（55.8%）为女性，中位（IQR）年龄为66（57-73）岁。与对照组相比，非脂肪组患者痴呆患病率较低（优势比[OR] 0.58, 95% CI 0.50-0.68，校正OR [aOR] 0.47, 95% CI 0.40-0.56）。在随访期间（中位4.9年，IQR 2.2-8.2），非脂肪组和对照组的痴呆发病率相似（风险比[HR] 1.05, 95% CI 0.97-1.15，调整后的HR [aHR] 1.06, 95% CI 0.97-1.15）。阿尔茨海默氏痴呆症也获得了类似的结果(aOR 0.44, 95% CI 0.34-0.57；aHR 0.94, 95% CI 0.80-1.10)和血管性痴呆(OR 0.71, 95% CI 0.52-0.94, aOR 0.48, 95% CI 0.35-0.64；HR 1.29, 95% CI 1.08-1.53, aHR 1.13, 95% CI 0.95-1.35)以及敏感性分析。肾上腺切除术没有改变结果。结论：NOFAT与痴呆风险增加无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.